Annual report pursuant to Section 13 and 15(d)

NONCONTROLLING INTEREST

v3.8.0.1
NONCONTROLLING INTEREST
12 Months Ended
Dec. 31, 2017
Noncontrolling Interest [Abstract]  
NONCONTROLLING INTEREST

NOTE 18 – NONCONTROLLING INTEREST

 

As of December 31, 2017, Dr. Yu Zhou, director and Co-Chief Executive Officer of GenExsome who owned 40% of the equity interests of GenExosome, which is not under the Company’s control. The following is a summary of noncontrolling interest activities in the year ended December 31, 2017.

 

    Amount  
Noncontrolling interest at December 31, 2016   $  
Net loss attributable to noncontrolling interest     (585,360 )
Foreign currency translation adjustment attributable to noncontrolling interest     (34 )
Noncontrolling interest at December 31, 2017   $ (585,394 )